Skip to main content
. 2019 Feb 21;4(4):e125851. doi: 10.1172/jci.insight.125851

Figure 3. Cumulative incidence of venous thromboembolism.

Figure 3

Venous thromboembolisms (VTE) were monitored clinically and by lower extremity ultrasound at completion of the 2-month study. Shown is the proportion of patients remaining free of VTE through the course of the study. There were no primary VTE in either the 500-mg isoquercetin cohort (A) or the 1000-mg isoquercetin cohort (B). The cumulative incidence of all secondary VTE endpoints (i.e., superficial thrombosis and distal thrombosis) shown in blue for both the 500-mg cohort (C) and the 1000-mg cohort (D).